CAR-T Cell Therapy Market

Market Size

The global CAR-T cell therapy market, valued at USD 6.1 billion in 2025, is projected to reach USD 7.7 billion in 2026 and USD 15.6 billion by 2035, with a CAGR of 8.1% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

• Based on product, Carvykti accounts for the largest share of the CAR-T cell therapy market, owing to its strong clinical efficacy and growing adoption in the treatment of multiple myeloma.
• Based on the type of therapy, autologous CAR-T cell therapies capture the majority share of the market due to their proven clinical success, established regulatory approvals, and widespread commercial availability.
• Amongst different target antigens, CAR-T therapies targeting CD19 account for over 60% of the overall market share owing to their extensive use across multiple B-cell malignancies and strong clinical outcomes.
• With respect to target indication, multiple myeloma contributes over 30% of the CAR-T cell therapy market due to the increasing adoption of BCMA-targeted therapies and rising treatment demand among relapsed / refractory patients.

• Across geographical regions, North America captures the largest share of the CAR-T cell therapy market owing to the presence of leading therapy developers, favorable reimbursement frameworks, advanced healthcare infrastructure, and high adoption of innovative cell therapies.

Market Overview

Cancer remains one of the leading causes of mortality worldwide, accounting for nearly 10 million deaths annually. Despite significant advances in oncology, many patients with relapsed or refractory cancers continue to face limited treatment options and poor clinical outcomes. As a result, there is a growing need for innovative cancer therapeutics capable of delivering durable and targeted anti-tumor responses.

CAR-T cell therapy has emerged as a major breakthrough in cancer immunotherapy, leveraging genetically engineered T cells to recognize and eliminate cancer cells. The therapy has demonstrated significant clinical success in several hematological malignancies and continues to expand into new therapeutic applications, driving growing interest among researchers, healthcare providers, and industry stakeholders.

Developers are actively investing in next-generation CAR-T technologies, including allogeneic, in vivo, armored, dual-target, switchable, logic-gated, and gene-edited CAR-T platforms, to improve efficacy, safety, scalability, and applicability across broader patient populations. At the same time, industry stakeholders are prioritizing manufacturing innovation to enhance scalability and commercial feasibility. For instance, in March 2026, Sartorius launched its Eveo Cell Therapy Platform, an automated manufacturing system designed to address scalability bottlenecks in cell therapy production and potentially reduce manufacturing costs associated with CAR-T therapies.

Despite growing clinical adoption, the industry continues to face challenges related to manufacturing complexity, lengthy production timelines, high treatment costs, and therapy-associated toxicities. Nevertheless, ongoing advances in cell engineering, manufacturing technologies, and next-generation CAR-T platforms are expected to create significant opportunities within the CAR-T cell therapy market.

Recent Developments

YOE: Year of Establishment

CAR-T Cell Therapy Market Trends

• Partnerships and Collaborations: The CAR-T cell therapy market is witnessing a growing number of collaborations among therapy developers, technology providers, contract manufacturers, and healthcare institutions. These partnerships are primarily focused on improving manufacturing efficiency, accelerating clinical development, and expanding patient access to cell therapies. For instance, in January 2026, Applied Cells and Immuneel Therapeutics entered into a strategic collaboration to evaluate advanced manufacturing workflows aimed at improving the affordability and accessibility of CAR-T therapies, reflecting the industry's growing focus on scalable and cost-efficient manufacturing solutions.
• Growing Focus on Allogeneic CAR-T Therapies: Developers are increasingly prioritizing allogeneic CAR-T therapies to overcome the manufacturing and logistical limitations associated with autologous treatment approaches. Unlike patient-specific therapies, allogeneic products can be manufactured in advance and potentially supplied to a larger patient population. For instance, in June 2026, Cellectis presented final Phase I results for lasme-cel, an allogeneic CAR-T therapy candidate for acute lymphoblastic leukemia, and preliminary clinical results for eti-cel, an allogeneic CAR-T therapy candidate for non-Hodgkin lymphoma.
• Expansion of CAR-T Applications Beyond Hematological Malignancies: The CAR-T field is rapidly expanding beyond traditional blood cancer indications into autoimmune diseases, solid tumors, and other complex disorders. Researchers are increasingly exploring the ability of engineered immune cells to selectively eliminate pathogenic cells and restore immune function. In June 2026, researchers from University College London presented results from a phase I clinical study, demonstrating that CAR-T therapy induced remission in patients with severe, treatment-resistant lupus. Such findings highlight the growing potential of CAR-T technologies beyond oncology and support continued research across autoimmune and other non-oncological indications.
• Emergence of In Vivo CAR-T Technologies: Companies are increasingly investing in in vivo CAR-T therapies that can generate CAR-T cells directly within the patient's body, eliminating the need for complex ex vivo cell manufacturing processes. This approach has the potential to simplify treatment delivery, reduce manufacturing complexity, and improve patient accessibility. For instance, in June 2026, Legend Biotech reported promising early clinical results for its in vivo CAR-T candidate LB2501 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, demonstrating growing momentum behind next-generation CAR-T technologies.
• Funding and Investments: In recent years, investors have continued to allocate substantial capital toward next-generation CAR-T technologies aimed at improving treatment accessibility, manufacturing efficiency, and clinical outcomes. For instance, in May 2026, Create Medicines secured USD 122 million in Series B financing to advance its RNA-based in vivo CAR-T therapies for cancer and autoimmune conditions.

Industry Experts on CAR-T Cell Therapy Market

The CAR-T cell therapy domain is entering a new phase of growth, driven by expanding applications beyond oncology. Highlighting this trend, Peter Cook (Senior Research Scientist, Seattle Children's Research Institute) stated, "Over the past few years, interest in applying chimeric antigen receptor T-cell (CAR-T) therapy approaches to autoimmune disease indications has rapidly grown."

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

• Head of Corporate Communications and Investor Relations, Mid-sized Company, US
• Former Chief Executive Officer, Small Company, Netherlands
• Chief Executive Officer, Founder and Chairman, Mid-sized Company, China
• Former Chief Operating Officer, Small Company, France
• Former Vice President, Large Company, US
• Former Vice President Immuno-Oncology, Small Company, Belgium
• Director Business Development, Small Company, US
• Former Competitive Intelligence Manager, Small Company, France
• Professor, Non-industry, China
• Assistant Professor, Non-industry, US

In addition, the market report includes transcripts of the following other third-party discussions:

• Chief Executive Officer, Mid-sized Company, US
• Chief Executive Officer, Small Company, US
• Chief Executive Officer, Mid-sized Company, US
• Director, Small Institute, US
• Clinical Director, Large Institute, US
• Senior Vice President, Cell Therapy Franchise, Very Large Organization, US
• Executive Vice President of Research & Development and Chief Medical Officer, Mid-sized Company, US
• Vice Chair, Center for ImmunoTherapy & Precision Immuno-Oncology, Large Company, US
• Chief Medical & Development Officer, Mid-sized Company, US
• Former Executive Director, Small Institute, US

Market Drivers

• Rising Prevalence of Hematological Malignancies and Relapsed / Refractory Cancers: The growing incidence of blood cancers, including lymphoma, leukemia, and multiple myeloma, continues to drive demand for advanced treatment modalities. As a significant proportion of patients experience relapses or become refractory to conventional therapies, CAR-T cell therapies offer a highly targeted approach capable of delivering durable responses and improving survival outcomes.
• Expanding Regulatory Approvals and Label Expansions: Increasing approvals of CAR-T therapies across multiple indications are accelerating market growth. Regulatory agencies are approving CAR-T products for broader patient populations while also supporting the development of next-generation therapies through accelerated pathways. For instance, in March 2026, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Caribou Biosciences' CB-011, an allogeneic anti-BCMA CAR-T cell therapy being developed for relapsed or refractory multiple myeloma.
• Technological Advancements in Cell Engineering and Manufacturing: Continuous innovations in genome editing technologies, vector design, automated manufacturing platforms, and allogeneic CAR-T development are improving product efficacy, reducing manufacturing timelines, and enhancing scalability. These advancements are expected to address key commercialization challenges and support broader market penetration.

Market Segmentation Analysis

Carvykti Leads the CAR-T Cell Therapy Market

On the basis of product, the global market is segmented into Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta.

Currently, Carvykti accounts for the largest share of the CAR-T cell therapy market. This dominance is primarily driven by its strong commercial performance in relapsed or refractory multiple myeloma, expanding treatment-center availability, and growing adoption across earlier lines of therapy. It is also worth highlighting that in 2025, Carvykti generated approximately USD 1.9 billion in net trade sales and was used to treat more than 10,000 patients globally, highlighting its strong market position.

Breyanzi is likely to witness the highest CAGR during the forecast period till 2035. This growth is due to its expanding approval base across multiple B-cell malignancies and increasing adoption among eligible patients. Additionally, in 2025, Breyanzi generated USD 1.36 billion in revenue, reflecting 82% year-on-year growth. It also received FDA approval for marginal zone lymphoma in December 2025, further strengthening its growth potential across hematological malignancies.

Autologous CAR-T Cell Therapies Continue to Dominate Clinical Applications

Based on type of therapy, the CAR-T cell therapy market is segmented into autologous CAR-T cell therapies and allogeneic CAR-T cell therapies.

The autologous CAR-T cell therapy segment accounts for the majority share of the market. This dominance is primarily due to the commercial availability of approved autologous products, strong clinical adoption across hematological malignancies, and established treatment workflows using patient-derived T cells. Most approved CAR-T products, including Carvykti, Breyanzi, Abecma, Kymriah, Yescarta, and Tecartus, are autologous therapies, thereby reinforcing the segment's current leadership.

Meanwhile, the allogeneic CAR-T cell therapies segment is likely to grow faster than autologous CAR-T cell therapies during the forecast period till 2035. This growth is due to its off-the-shelf treatment potential, ability to shorten therapy administration timelines, and capacity to reduce dependence on patient-specific manufacturing. As developers continue to address key challenges such as graft-versus-host disease, immune rejection, and cell persistence, allogeneic CAR-T platforms are likely to gain stronger clinical and commercial relevance over the coming years.

CD19 Target Antigen Anchors the CAR-T Cell Therapy Market

Based on target antigen, the CAR-T cell therapy market is segmented into CD19, BCMA, CD20, CD19/22, and other target antigens.

In 2026, the CD19 segment accounted for more than 60% of the overall CAR-T cell therapy market. This dominance is primarily due to the broad clinical validation of CD19 as a target across B-cell malignancies, including acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. The strong commercial presence of multiple CD19-targeting CAR-T products, including Kymriah, Yescarta, Breyanzi, and Aucatzyl, has further reinforced the segment's leading market position.

The BCMA segment is likely to register the highest CAGR during the forecast period till 2035. This growth is due to the increasing adoption of BCMA-directed CAR-T therapies in multiple myeloma, supported by strong clinical outcomes, expanding use across earlier treatment lines, and growing physician confidence in this target class. Commercial momentum from BCMA-targeting products, particularly Carvykti and Abecma, is likely to strengthen the role of BCMA as a high-growth target antigen in the CAR-T cell therapy market.

Multiple Myeloma to Drive Adoption of CAR-T Cell Therapies

Based on target indication, the CAR-T cell therapy market is segmented into acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, large B-cell lymphoma, mantle cell lymphoma, multiple myeloma, and others.

Currently, the multiple myeloma segment accounts for more than 30% of the overall CAR-T cell therapy market. This dominance is primarily due to the high treatment burden associated with relapsed or refractory multiple myeloma, repeated relapse patterns, and the need for effective treatment options among patients who have exhausted standard therapies. It is worth highlighting that the FDA has approved two BCMA-targeting CAR-T therapies for patients with multiple myeloma after one or two prior lines of therapy. This has significantly expanded the eligible patient population.,

The large B-cell lymphoma segment is likely to witness the highest growth during the forecast period. This growth is due to the sizeable patient population, high relapse rates after conventional therapies, and increasing clinical adoption of CAR-T therapies in patients with relapsed or refractory disease. Continued evaluation of CAR-T therapies in earlier treatment settings is expected to expand the eligible patient pool and support stronger adoption across the large B-cell lymphoma segment.

Market Regional Insights

In terms of geographical regions, the global CAR-T cell therapy market is distributed across North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World.

North America Dominates the Market

According to our analysis, North America captures the largest share of the CAR-T cell therapy market. This dominance is primarily due to the early approval and commercialization of several CAR-T therapies in the US, well-established treatment-center networks, and a favorable reimbursement framework for FDA-approved CAR-T products. Notably, the US has approved multiple commercial CAR-T therapies across hematological malignancies, while Medicare provides coverage for FDA-approved autologous CAR-T therapies when administered at approved healthcare facilities.

At the same time, the US regulatory environment is evolving, as the FDA has outlined a New Superiority Standard under which future CAR-T approvals may require stronger comparative evidence, including randomized studies designed to demonstrate superiority over existing treatment options. This shift is expected to make the approval pathway more rigorous for new entrants, while encouraging developers to generate more robust clinical data for next-generation CAR-T products. These factors have supported stronger clinical adoption, patient access, and commercial revenue generation, strengthening North America's leadership in the global CAR-T cell therapy market.

CAR-T Cell Therapy Market in Asia Pacific to Show Strong Growth Momentum

The CAR-T cell therapy market in Asia-Pacific is likely to grow at the highest rate during the forecast period. This growth is supported by rapid clinical development activity, domestic product approvals, and expanding regional manufacturing capacity. This momentum is particularly evident in China, which has emerged as one of the most active CAR-T research hubs globally, accounting for 1,006 of 1,908 CAR-T clinical trials identified globally in 2026. In India, the approval of NexCAR19, the country's first indigenous CAR-T therapy, has improved access to an affordable domestic treatment option and is expected to support broader adoption among eligible cancer patients. Similarly, AstraZeneca's 2026 plan to establish a commercial cell therapy manufacturing and supply base in Shanghai to produce CAR-T therapies for China and broader Asian markets is expected to strengthen regional supply capacity and support commercialization of advanced cell therapies across Asia-Pacific.

CAR-T Cell Therapy Market: Scope of the Report

Market Segments

Based on our research, we have segmented the CAR-T cell therapy market into product, type of therapy, target antigen, target indication and geographical regions.

By Product

• Abecma
• Breyanzi
• Carvykti
• Kymriah
• Tecartus
• Yescarta

By Type of Therapy

• Autologous CAR-T Cell Therapies
• Allogeneic CAR-T Cell Therapies

By Target Antigen

• CD19
• BCMA
• CD20
• CD19/22
• Other Target Antigens

By Target Indication

• Acute Lymphoblastic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma
• Others

By Geographical Regions

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and North Africa
• Rest of the World

Frequently Asked Questions

Question 1: What is CAR-T cell therapy?

Answer: CAR-T cell therapy is a genetically enhanced T-cell therapy or adoptive T-cell therapy that harnesses the innate potential of immune cells, specifically T-cells, to potentially combat a variety of diseases.

Question 2: How big is the market for CAR-T cell therapy?

Answer: The global CAR-T cell therapy market is projected to reach USD 15.6 billion by 2035.

Question 3: What is the CAR-T cell therapy market growth rate?

Answer: The market size for CAR-T cell therapy is likely to grow at a CAGR of 8.1% during the forecast period till 2035.

Question 4: What are the disadvantages of CAR-T cell therapy?

Answer: CAR-T cell therapies have several disadvantages, including significant side effects, high costs, and limitations in their effectiveness for certain cancers. These include cytokine release syndrome (CRS), neurotoxicity, and a weakened immune system, leading to increased infection risk.

Question 5: What is the current status of CAR-T cell therapy?

Answer: CAR-T cell therapy is a highly promising cancer treatment, particularly for blood cancers, and is currently approved for several types of B-cell malignancies and multiple myeloma.

Question 6: How many clinical trials are running for CAR-T therapies?

Answer: There are more than 2,000 active trials for CAR-T cell therapies.